House Bill 249

Actions
Last Action 01/21/20: posted in committee
Title AN ACT relating to prescription drugs.
Bill Documents Introduced
Fiscal Impact Statement Health Mandate
Bill Request Number 25
Sponsors D. Bentley, T. Bojanowski, R. Bridges, D. Frazier, K. King, C. Massey, P. Minter, P. Pratt, M. Sorolis, C. Stevenson, R. Webber, S. Westrom
Summary of Original Version Create various new sections of KRS Chapter 315 to define terms; to require the Cabinet for Health and Family Services to annually compile lists of certain prescription drugs deemed to be essential to treating diabetes; to require drug manufacturers to annually report to the cabinet certain information related to the cost of manufacturing and marketing such drugs and factors that contributed to any price increase; require pharmacy benefit managers to annually report to the cabinet certain information related to prescription drug rebates for such drugs; to require the cabinet to annually submit to the Legislative Research Commission a report that summarizes the information provided to the cabinet by manufacturers and pharmacy benefit managers; to exempt information and data reported by manufacturers and pharmacy benefit managers to the cabinet from disclosure pursuant to KRS 61.870 to 61.884; to require the cabinet to promulgate administrative regulations; amend KRS 315.990 to establish a penalty for failure to report; amend KRS 304.17A-164 to restrict cost-sharing amounts charged by insurers and pharmacy benefit managers; to prohibit insurers and pharmacy benefit managers from restricting a pharmacist's ability to inform patients about and to sell less expensive alternative drugs; amend KRS 304.17A-505 and 304.17C-030 to require disclosure of information related to drug formularies; to create various new sections of KRS Chapter 367 to define terms; to prohibit manufacturers and wholesalers of off-patent or generic prescription drugs from engaging in unrestricted price increases; to require the secretary of the Cabinet for Health and Family Services to report certain price increases to the Attorney General; to establish that certain price increases for off-patent or generic drugs constitute a violation of KRS 367.170; to establish penalties; and certain sections EFFECTIVE January 1, 2021.
Index Headings of Original Version Diseases - Diabetes, insulin price reporting requirements, establishment of
Drugs and Medicines - Insulin, price reporting requirements, establishment of
Drugs and Medicines - Prescription drugs, unrestricted price increases, prohibition of
Insurance, Health - Cost-sharing amounts, restrictions on
Insurance, Health - Drug formulary changes, require disclosure of
Pharmacists - Sale of less expensive alternative drugs, permitted
Administrative Regulations and Proceedings - Cabinet for Health and Family Services, prescription drug price reporting
Attorney General - Prescription drugs, unrestricted price increases, prohibition of
Reports Mandated - Cabinet for Health and Family Services, insulin drug prices
Effective Dates, Delayed - Cost-sharing amounts, restrictions on
Effective Dates, Delayed - Drug formulary changes, require disclosure of
Health Benefit Mandate - Prescription drug price reporting

Actions

Top
01/13/20
  • introduced in House
01/15/20
  • to Health and Family Services (H)
01/21/20
  • posted in committee


Last updated: 4/3/2020 3:41 PM (EDT)
To receive notice when the record is updated follow @LRCTweetBot.